QIMR Berghofer researchers create drugs for Covid-19
QIMR Berghofer Medical Research Institute scientists create two peptide-based drugs for Covid-19 prevention and treatment.
Noxopharm’s Veyonda prevents cytokine storm in Covid-19 trial
Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its...
Australian TGA approves Vertex’s Trikafta for cystic fibrosis treatment
The Australian Therapeutic Goods Administration (TGA) has approved the use of Vertex Pharmaceuticals’ Trikafta (elexacaftor,...
Australia approves Pfizer-BioNTech’s Covid-19 vaccine
Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer-BioNTech Covid-19 vaccine for use in...
Seqirus’ Influenza Vaccine Manufacturing Facility, Melbourne
Seqirus, an influenza vaccine maker, is building a new cell-based influenza vaccine manufacturing facility in...
Mesoblast signs ARDS therapy development deal with Novartis
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of...
Breast cancer breakthrough: could a new therapy silence stubborn TNBC?
Despite significant advances in breast cancer treatments over the last half century, one subtype of...
Australia to acquire 40 million doses of Novavax Covid-19 vaccine
Novavax has signed a non-binding Heads of Terms document with the Australian government to supply...
Ena Respiratory’s nasal spray shows promise against Covid-19
Australian biotech company Ena Respiratory has said that its nasal spray has significantly mitigated Covid-19...
